Nurses and NPs share how they manage rash, stomatitis, diarrhea, dose holds, cost, and trial eligibility with oral daraxonrasib in pancreatic cancer.
|Articles|May 24, 2011
Janet Hampton on the Distress Thermometer Study Results
Author(s)Janet Hampton, RN, BS
Janet Hampton University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results
Advertisement
Janet Hampton, RN, BS, OCN® from the University of Michigan Health System Cancer Center Explains Distress Thermometer Study Results
Advertisement
Related to this article
As bispecifics and cell therapies move outpatient, Kate Kennedy, MSN, APRN, says nurses and APPs should focus on education and atypical infections.
A 3-minute video and quick-reference list of October's 7 FDA cancer approvals, with the biomarker and monitoring points nurses need for each.
Oral vitamin C did not slow clonal growth in the phase 2 EVITA trial but was linked to longer survival.
Kathryn Shady, PhD, RN, OCN, discusses research on emotional dissonance and vicarious trauma among hematology/oncology nurses.
Ellery Palanuk, MSN, RN, CN-BN, explains how navigators rely on multidisciplinary teams and tumor boards as breast cancer treatment evolves.
At EONS 2026, a City of Hope nurse practitioner explains how shifting immunotherapy from infusion to injection can free nurse and chair time.
Oncology nurses play a key role guiding patients about AI breast cancer risk assessment tools, dynamic re-testing, and individualized screening plans.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Daraxonrasib and RAS Inhibition: What Oncology Nurses Need to Know
2
Childhood Leukemia Treatment Disrupts Work, Finances for Most Families
3
October 2026 FDA Approvals: 7 Cancer Updates for Oncology Nurses
4
What Nurses Should Tell Patients About Vitamin C in CCUS and MDS
5